Loading…
Loading…
EAPIF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for EAPIF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EAPIF and 80,000+ other tickers.
See exactly how EAPIF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EAPIF and 80,000+ other tickers.
Established in 2021 and headquartered in Paris, France, Euroapi SA specializes in the end-to-end process, from development and manufacturing to marketing and distribution, of active pharmaceutical ingredients (APIs) and various intermediary compounds. These essential materials are then utilized in the formulation of a wide array of medicinal products for both human and veterinary applications.
Euroapi S.A. (EAPIF) Q2 2026 Earnings Call Transcript
Press Release Paris – May 13, 2026 – EUROAPI takes note of local media reports regarding its Brindisi site. As previously communicated, the review of strategic options for certain industrial assets is progressing in line with the Group's FOCUS-27 transformation plan, with the objective of completing the related processes by the end of 2027.
Press Release Availability of the 2025 Universal Registration Document, including the Annual Financial Report Paris – March 27, 2026 – EUROAPI announces the publication of its 2025 Universal Registration Document in ESEF format, filed with the French Autorité des marchés financiers (AMF) on March 27, 2026. The 2025 Universal Registration Document contains in particular: The annual financial report, including the management report that encompasses namely the Corporate Governance report, the sustainability statement and the company and consolidated statements; The statutory auditors' reports, including the special report on the regulated agreements; The disclosures relating to statutory auditors' fees; and The disclosures relating to the description of the share buy-back program.
Euroapi S.A. (EAPIF) Q4 2025 Earnings Call Transcript
Euroapi S.A. (OTCMKTS:EAPIF - Get Free Report) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 46,171 shares, a growth of 110.6% from the December 31st total of 21,924 shares. Based on an average trading volume of 3 shares, the days-to-cover ratio is